BlossomHill Therapeutics, Inc. (BLSM) fair value analysis
Nasdaq · Updated 2026-10-19
BLSM price how computed
Valuation status
No fair-value estimate yetBLSM has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BLSM yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $13.94
- Sector
- Healthcare
- 12-month range
- $13.94–$18.99
- Market cap
- $443M
- From 52-week high
- -26.6%
- Shares outstanding
- 31.8M
- Rank in Healthcare by quality score
- #225 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
BlossomHill Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutic treatments for patients with serious diseases. The company operates in the United States and conducts research and development activities to advance its pipeline of drug candidates across various therapeutic areas.
BLSM currently ranks #225 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $443M
- Debt / equity
- 0.28
- Shares outstanding
- 31.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 21 · oversold
Earnings how computed
- Last 1 quarters vs consensus
- 0 beat, 1 missed
- Quarter by quarter
- 2026-06 ▼ miss (-941.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Consensus price target
- $35.4
- Target vs last price
- +153.9%
What our data shows for BLSM
- Shares are trading in the lower third of their 12-month price range of $13.94–$18.99.
- The 14-day relative strength index sits at an oversold 21.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BLSM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BLSM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — BLSM's RSI indicator moved into oversold territory this week, shifting from a neutral zone status. The Healthcare sector stock's current valuation assessment remains pending full analysis. This technical indicator change suggests the stock may have experienced downward price momentum recently.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BLSM stock undervalued?
TickrTrends has no fair-value estimate for BLSM yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BLSM's TickrTrends verdict?
BLSM is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BLSM compare to other Healthcare stocks?
BLSM ranks #225 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BLSM overbought or oversold?
BLSM's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does BLSM usually beat earnings estimates?
Over its last 1 reported quarters BLSM beat the consensus estimate 0 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.